Novartis AG - Company Profile
Powered by
All the data and insights you need on Novartis AG in one report.
- Save hours of research time and resources with
our up-to-date Novartis AG Strategy Report
- Understand Novartis AG position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View moreNovartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. Novartis conducts research in various disease areas through the BioMedical Research division. The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
Novartis AG premium industry data and analytics
Products and Services
Products | Brands |
---|---|
- | Exforge (valsartan and amlodipine besylate) |
Generic Medicines and Biosimilars | Exforge HCT (valsartan, amlodipine besylate and hydrochlorothiazide) |
Pharmaceuticals: | Diovan (valsartan) |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Contracts/Agreements | In May, the company entered into an agreement to acquire Mariana Oncology for US$1 billion. |
2024 | Contracts/Agreements | In April, the company entered into an agreement with Arvinas to develop and commercialize ARV-766, a new treatment for prostate cancer. |
2024 | Regulatory Approval | In April, the company secured approval from the U.S. Food and Drug Administration for Lutathera to treat pediatric patients 12 years and older with somatostatin receptor-positive |
Competitor Comparison
Key Parameters | Novartis AG | Johnson & Johnson | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Pfizer Inc |
---|---|---|---|---|---|
Headquarters | Switzerland | United States of America | Switzerland | United States of America | United States of America |
City | Basel | New Brunswick | Basel | Kenilworth | New York |
State/Province | - | New Jersey | - | New Jersey | New York |
No. of Employees | 76,057 | 131,900 | 103,605 | 72,000 | 88,000 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Joerg Reinhardt, Ph.D. | Chairman | Executive Board | 2013 | 68 |
Vasant Narasimhan, M.D. | Chief Executive Officer | Senior Management | 2018 | 48 |
Harry Kirsch | Chief Financial Officer | Senior Management | 2013 | 59 |
Karen L. Hale | Chief Legal Officer | Senior Management | 2021 | 56 |
Shreeram Aradhye | Chief Medical Officer; President - Global Drug Development | Senior Management | 2022 | 62 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer